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Abstract
Background: Preventative medication reduces hospitalisations in people with cystic fibrosis (PWCF) but adherence
is poor. We assessed the feasibility of a randomised controlled trial of a complex intervention, which combines
display of real time adherence data and behaviour change techniques.
Methods: Design: Pilot, open-label, parallel-group RCT with concurrent semi-structured interviews. Participants:
PWCF at two Cystic Fibrosis (CF) units. Eligible: aged 16 or older; on the CF registry. Ineligible: post-lung transplant or
on the active list; unable to consent; using dry powder inhalers. Interventions: Central randomisation on a 1:1 allocation to:
(1) intervention, linking nebuliser use with data recording and transfer capability to a software platform, and behavioural
strategies to support self-management delivered by trained interventionists (n = 32); or, (2) control, typically face-to-face
meetings every 3months with CF team (n= 32). Outcomes: RCT feasibility defined as: recruitment of ≥ 48 participants
(75% of target) in four months (pilot primary outcome); valid exacerbation data available for ≥ 85% of those randomised
(future RCT primary outcome); change in % medication adherence; FEV1 percent predicted (key secondaries in future
RCT); and perceptions of trial procedures, in semi-structured interviews with intervention (n= 14) and control (n = 5)
participants, interventionists (n = 3) and CF team members (n = 5).
Results: The pilot trial recruited to target, randomising 33 to intervention and 31 to control in the four-month period,
June–September 2016. At study completion (30th April 2017), 60 (94%; Intervention = 32, Control =28) participants
contributed good quality exacerbation data (intervention: 35 exacerbations; control: 25 exacerbation). The mean change
in adherence and baseline-adjusted FEV1 percent predicted were higher in the intervention arm by 10% (95% CI: -5.2 to
25.2) and 5% (95% CI -2 to 12%) respectively. Five serious adverse events occurred, none related to the intervention. The
mean change in adherence was 10% (95% CI: -5.2 to 25.2), greater in the intervention arm. Interventionists delivered
insufficient numbers of review sessions due to concentration on participant recruitment. This left interventionists insufficient
time for key intervention procedures. A total of 10 key changes that were made to RCT procedures are summarised.
Conclusions: With improved research processes and lower monthly participant recruitment targets, a full-scale
trial is feasible.
Trial registration: ISRCTN13076797. Prospectively registered on 07/06/2016.
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Background
Cystic Fibrosis (CF) is an inherited long-term condi-
tion affecting over 80,000 people worldwide [1–5],
mostly in people of Northern European ancestry [6].
People with cystic fibrosis (PWCF) typically die from
lung damage at a median age of 31 years [1]. Preventa-
tive medications reduce exacerbations and preserve
lung function [7–13]. There is a disparity between
self-reported and objectively measured adherence to
inhaled therapy, with recorded rates of 80 and 36% re-
spectively [14]. It follows that, currently, clinicians are
not able to identify people with low adherence and
offer appropriate support. Low adherence predicts ex-
acerbations requiring intravenous antibiotics (IVAB)
[15, 16], which carry a risk of systemic side effects and
increased mortality [17, 18], and result in higher care
costs [19–21]. During 2012 the total UK spend for CF
was estimated to be £110 million [22]of which £30
million was spent on inhaled antibiotics and muco-
lytics [23]; the following year the UK adults with CF
population received 103,453 days of IVAB [24] with
54% occurring in hospital, [25].
Consistent with identified research priorities [26,
27], we developed a complex intervention to support
adherence to preventive inhaled therapy. This paper
summarises the intervention development process,
presenting the results of the pilot randomised con-
trolled trial (RCT) component of the feasibility study,
and describing the resulting changes made to the
intervention and research procedures, in advance of a
full-scale RCT [28, 29].
The specific objectives of the feasibility study were:
1. To determine feasibility of a RCT based on:
(a) participant recruitment;
(b) participant retention;
(c) quality of primary outcome and other data at 5(+/−
1) month; and
(d) the acceptability and robustness of trial procedures
2. To carry out a process evaluation, consisting of
quantitative and qualitative data on procedures
and outcomes, in order to understand and mitigate
potential sources of intervention failure in terms of
contextual effects, inputs, engagement, activities
and outcomes. The specifics of the process
evaluation are detailed in a separate article,
dedicated to this aspect of the study.
3. To document changes to research and intervention
procedures for a future RCT, based on the findings.
Changes to research procedures only will be
documented in this report.
Methods
Design
The feasibility study in preparation for the full RCT con-
sisted of a concurrent pilot RCT and a mixed methods
process evaluation. The objectives of the pilot RCT were
to determine feasibility of a full-scale RCT based on par-
ticipant recruitment/retention, the quality of primary
outcome data and the acceptability and robustness of
trial procedures. This was a parallel group, open label,
individually-randomised external pilot RCT with a 1:1
allocation ratio with additional semi-structured inter-
views. The protocol is available (Additional file 1); this
report is compliant with Consolidated Standards of
Reporting Trials (CONSORT) extension for randomised
pilot studies [30] (Additional file 2).
Participants
We planned to recruit 64 participants between 1st June
2016 and 30th September 2016 from two CF Centres
(Nottingham University Hospitals and University Hospital
Southampton). The CF registry provided a list of poten-
tially eligible patients for each site. Medical notes were
then reviewed to select those aged 16 years and over, tak-
ing – or willing to take – inhaled mucolytics or antibiotics
via a nebuliser with data recording and transfer capability.
We excluded those who were: post-lung transplant, on the
active transplant list, receiving palliative care, lacking cap-
acity for informed consent, or using dry powder devices to
take antibiotics or mucolytics.
A purposive sample of intervention arm (n = 14) and
control arm participants (n = 5), as well as intervention-
ists (n = 3 0.8 WTE at each centre) and members of the
wider, multi-disciplinary CF team (n = 5) was used to
conduct semi-structured interviews, assessing accept-
ability and robustness of RCT procedures. Participants
were selected based on site, age, gender and deprivation
index. Postcodes were used to generate an Index of
Multiple Deprivation (IMD) quintile. Service-users were
selected based on objective and subjective adherence
levels (respectively indicated by nebuliser-recorded in-
halation data and a self-report question administered at
baseline, asking “Thinking back to the last two weeks.
What percentage of your nebuliser treatments have you
taken?”). Professionals were selected based on site and
professional category.
Consent and randomisation
Eligible participants were invited to give written informed
consent to engage in the pilot RCT. For most participants
we obtained consent to have their adherence data col-
lected beyond their active trial period, until 30 April 2017.
Participants were randomised to intervention or control
arms using a computer-generated pseudo-random list and
random permuted blocks of varying sizes (2,4 and 6),
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stratified by site and number of IVAB days in the previous
12months (≤/> 14 days) [24].
PWCF that consented to be approached for interview
were contacted by letter or mail and subsequently tele-
phone or email, dependent on preference. Professionals
were contacted directly by the study team. Patients were
interviewed once and interventionists were interviewed at
both the beginning and the end of the study. Semi-struc-
tured interviews were conducted face-to-face, digitally
audio-recorded and verbatim transcribed.
The complex intervention
The intervention has four elements, two of which are
also used for data collection purposes in the control arm
of the trial
1. eTrack (PARI Pharma GmbH, Starnberg, Germany)
nebulisers to deliver inhaled medications and
provide monitoring functions. eTrack nebulisers
send timestamped inhalation data to a 2net Hub
(Qualcomm, San Diego, USA), which enables real-
time monitoring. The devices could not distinguish
between different drugs administered through the
nebuliser; whilst it is theoretically possible for
patients to press different buttons depending on the
drug, our experience is that any additional step in
nebuliser therapy decreases the probability that it
will be completed. In addition, relying on participants
pressing buttons to distinguish between drugs may
have introduced an additional source of error if
buttons were incorrectly used;
2. CFHealthHub server infrastructure receives the
inhalation data in real-time from PARI, stores the
data securely and presents this for display on the
CFHealthHub apps (see Fig. 2);
3. CFHealthHub apps – with behaviour change
tools and educational content to render the
received data and present it to clinicians via the
website, and to patients via website and mobile
apps; and,
4. A manualised behaviour change intervention used
by trained health professionals in their interactions
with PWCF.
Both intervention and control groups received a nebu-
liser with data recording and transfer capability, which
measured their adherence to medication. The adherence
data for the control group was not visible to partici-
pants, interventionists or the care team throughout the
trial. In the intervention group, the adherence data was
visible to the interventionist only for a two- to four-
week baseline period, following this it was also made vis-
ible to both the participants and care team. The control
group continued with usual care.
The intervention group had access to: (1) informa-
tion technology infrastructure which captures, stores
and displays adherence data; (2) online adherence
feedback and tailored modules of behaviour change
content; (3) an initial visit, and at least one additional
review visit, from a trained interventionist who deliv-
ered face-to-face behaviour change content. The be-
haviour change content was linked to online content
and therapists provided support and guidance in line
with, and interacting with this. Interventionists were
trained through a two-day, face-to-face workshop, on-
line learning modules and a structured four-week
training programme, with an online theory test and
competency assessment of the intervention delivery
within the first 5 sessions.
Summary of the intervention development process
The intervention was developed as follow: The Sheffield
Microsystems Coaching Academy [31] worked with the
Sheffield adult CF team to carry out a “Five Ps” strategic
analysis [32]. The CF team identified their overarching
purpose to be to enable PWCF to live as normal a life as
possible and their objective to shift from disruptive
hospital-based rescue to community-based prevention
[33]. Understanding the link between medication adher-
ence and preserved lung function [7–13], our aim became
that PWCF should lose less than 2% of lung function each
year. We reviewed the evidence for barriers to adherence
to CF medication and the effectiveness of interventions
for improving adherence [34, 35]. We used a quality
improvement technique, process mapping [36], which
highlighted the need for objective medication adherence
data in the CF unit. Software engineers developed data
capture, download and feedback systems for nebulisers.
We used statistical process control to analyse data logged
by nebulisers, thereby better understanding common and
special cause variation in adherence [37, 38]. We modelled
the use of adherence indices which take into account the
percentage of the regimen taken and its appropriateness
[39]. We explored barriers and beliefs about adherence
[40, 41], using objective adherence data as a prompt in in-
terviews [42] and the Theoretical Domains Framework
(TDF) [43–45] to analyse the barriers and facilitators. We
used the ‘COM-B’ system [46], the behaviour change
wheel [47, 48] and TDF [43] to identify suitable interven-
tion functions and behaviour change techniques with
reference to two theories of behaviour: Social Cognitive
Theory [49], which emphasises the importance of self-effi-
cacy, outcome expectancies, environmental factors, and
goal setting on behaviour; and, Control Theory [50], which
suggests that self−/monitoring and feedback are effective
in closing the gap between reality and goals, thereby pro-
moting habit formation. We used a Markov model to esti-
mate the incremental cost-effectiveness of adding an
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adherence intervention to control [51]. We produced a
logic model (Fig. 1) expressing the processes by which we
expected our intervention to work in terms of inputs, en-
gagement, activities and outcomes.
We produced the software platform, CFHealthHub
(Fig. 2), with feedback from PWCF, clinicians, the software
team and user experience (UX) design company, using
Agile methods [52, 53]. The platform is compliant with
regulatory, data protection, security and interoperability
standards [54–57]. Following best practice guidelines [58],
we used prototypes and wireframes to design the website
and mobile apps [59], combining evidence-based [60] and
user-centred design principles to define requirements,
refine the user interface and enhance usability [61].
Short-cycle software releases allowed rapid user feedback
and beta-testing of the digital platform by researchers, clini-
cians and patients (Additional file 3) [62–66]. Theory-based
user-engagement strategies, tracking and click analytics and
summaries of user ‘point-and-click’ web data, generated to
describe the individual’s online activity, were built into the
website and mobile apps. We incorporated short films,
some which explained how medications work, others in
which PWCF share experiences of forming treatment
adherence habits (‘talking heads’). The digital platform has
been running continuously since August 2015, receiving
and presenting inhalation data in real-time from Pari
eTrack nebulisers. Three physiotherapists gave verbal
feedback at two time-points during the development
of a training course, manual and reporting tools de-
veloped to guide and document interactions with pa-
tients using CFHH. Fidelity assessment sheets were
developed for these interactions based on the Na-
tional Institute for Health process [67, 68].
Sample size
In the proposed full-scale trial, we hoped that 15 CF units
would each recruit 46 patients in six months (8 patients
per centre per month). To match this rate, our two-centre
pilot needed to recruit 64 participants in its four-month
accrual window. To progress to a full-trial our recruitment
target was to consent and randomise 48 participants at
two centres over four months, which was 75% of the rate
required in the main trial. A second progression criterion
was attrition from contribution of exacerbation data of no
more than 15% of randomised participants at 5 (±1)
months. This sample would also give us sufficient confi-
dence to predict recruitment and retention in the
full-scale RCT with sufficient precision [69–72].
Fig. 1 Logic model
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Outcomes
Outcomes of interest mapped directly onto the objectives:
(a) participant recruitment of ≥ 48 participants (75% of
target) in four months;
(b) participant retention, defined as ≥ 85% of those
randomised contributing exacerbation data at study
completion;
(c) quality of primary outcome and other data at 5(+/− 1)
month. We assessed the ability of study staff to collect
valid data for the full-scale trial’s proposed primary
outcome, the number of pulmonary exacerbations.
Defined according to the modified Fuchs’ criteria [73],
a pulmonary exacerbation was said to have occurred if
a patient was treated with intravenous antibiotics for
any one of 12 signs or symptoms (Additional file 1).
An exacerbation form was administered by the site
interventionist at each clinical encounter, with every
study participant. The form captured whether there
was a clinical need for a course of IVABs, which Fuchs’
criteria were met and whether participants accepted
treatment IVABs. Secondary clinical outcomes are
listed in Table 1 and were collected as baseline and
5(+/− 1) month post-randomisation.
(d) the acceptability and robustness of trial procedures,
assessed through semi-structured interviews, reports
recorded on our log of problems, management group
and patient and public involvement (PPI) meetings.
There are three reasons for defining the primary out-
come in terms of the modified Fuchs’ criteria [73]. First,
to avoid excessive ascertainment bias in intervention
group participants who would be reviewed more fre-
quently. It follows that there is a higher chance of detecting
an exacerbation in this group. By setting a sufficiently high
bar, that is - an exacerbation deemed severe enough to re-
quire IVABs - we aim to prevent over-ascertainment of
mild exacerbations in the intervention group. The use of
IVABs is unlikely to be missed in either trial arm, since it is
administered by the CF team in an acute setting, whereas
oral antibiotics from general practitioner (GP) might be
underreported in the control group who are seen less fre-
quently. Second, the use of four or more symptoms - as in
the original Fuchs’ criteria - is a high threshold; by com-
parison, our use of one or more symptoms increases sensi-
tivity to CF symptoms. Finally, this definition is in use in
modern pivotal trials [73].
Data analysis
Details of participant screening, recruitment and reten-
tion were presented in a CONSORT flow diagram. Base-
line characteristics were presented by treatment arm and
overall.
The total number of exacerbations by participant and
by treatment arm were presented. As this was a pilot
study, definitive comparisons of interventions were not
undertaken, however point estimates of effect and their
95% confidence intervals were reported for primary and
secondary clinical outcomes [72, 74]. A primary effect-
iveness analysis was conducted on the primary clinical
outcome using a negative binomial model and adjusting
for number of IV days in the previous 12 months and
site. Incidence rate ratio (IRR) and 95% confidence inter-
vals were presented.
Adjusted mean difference in Forced Expiratory Volume
(FEV-1) percent predicted was estimated using a multiple
linear regression model adjusting for baseline and site. A
full statistical methods and descriptive statistics for all
Fig. 2 The digital platform
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secondary outcomes can be found in Additional file 4.
Trial statisticians remained blind until database freeze,
the point where all data had been input and all
known queries resolved. The intention-to-treat popu-
lation (primary analysis set) included all participants
for whom consent was obtained and who were rando-
mised to treatment, regardless of whether they
received the intervention or not [75]. We tested using
prescription and nebuliser data to calculate the total
number of doses and simple unadjusted adherence
[39]. Weekly numerator-adjusted normative adherence
[39] was calculated and a mean by treatment arm was cal-
culated and presented as a line graph. Data collected be-
yond the final intervention session, until 30th April
enabled us to understand whether flat-lining of the adher-
ence charts resulted from a technical fault or non-adher-
ence to prescribed medication. The number of adverse
events (AEs) and serious adverse events (SAEs) was pre-
sented by treatment arm.
Statistical analysis was performed using R version 3.4.1
statistical software [76].
A Framework analysis [77] of the semi-structured in-
terviews was undertaken to investigate the acceptability
of trial procedures for participating site staff and patients
[78]; additionally, we investigated whether control par-
ticipants had been “contaminated” by knowledge of, or
receipt of the intervention [79].
Approach taken to modifying research procedures
Modifications, arising from interviews, reports recorded
on our log of problems, management group and patient
and public involvement (PPI) meetings, were categorised
to do with: the software platform; the manual and train-
ing; and, the RCT procedures. Based on a modified ver-
sion of the approach taken by Bugge, we tabulated issues
and solutions [29]. We regularly reviewed priorities for
development of the digital platform using a system
known as, “Must have, Should have, Could have, and
Won’t have but would like” (MoSCoW) [28], frequently
used in agile software development [52, 53].
Patient and public involvement
The Patient and Public Involvement (PPI) Group were
recruited through leaflets placed in CF units, advertis-
ing on the People in Research website and snowballing.
They teleconferenced to prevent cross-infection be-
tween PWCF [80] and provided feedback on interven-
tion data-sharing policies, usability and presentation of
the website/user-guide; they piloted participant infor-
mation materials and one person also provided input
on the trial protocol and interview guides (Additional
file 1).
Ethical approval
The study received approval from London Brent Re-
search Ethics Committee (16/LO/0356). The funder was
not involved in the trial design, patient recruitment, data
collection, analysis, interpretation, or presentation, writ-
ing or editing of the report, or the decision to submit for
publication. The corresponding author had full access to
Table 1 Secondary clinical outcomes
Secondary outcomes
Body Mass Index (BMI).
Forced expiratory volume in 1 s (FEV1): standardised spirometry as a
measure of condition severity [100].
EuroQol EQ-5D-5 L: generic health status measure for health economic
analysis [101].
The Patient Activation Measure (PAM-13): assessment of patient
knowledge, skill, and confidence for self-management [102]. Elements
of the PAM-13 map to logic model constructs #29 and #30.
Confusion, Hubbub, and Order Scale (CHAOS 6-item): measure of life chaos
[103]. Elements of the CHAOS-6 map to logic model construct #32.
Medication Adherence Data-3 items (MAD-3). Bespoke questionnaire
adapted from the Medication Adherence Reporting Scale [104]:
1. I forget to take my nebuliser treatment (Always/Often/Sometimes/
Rarely/Never)
2. I take fewer nebuliser treatments than my doctor recommends
(Always/Often/ Sometimes/Rarely/Never)
3. I decide to skip one or more of my nebuliser treatments (Always/
Often/Sometimes/Rarely/Never)
Maps to logic model construct #28.
Self-Report Behavioural Automaticity Index (SRBAI) [105]. Maps to logic
model construct #31.
Cystic Fibrosis Questionnaire-Revised (CFQ-R): disease specific health-related
quality of life instrument [106].
The Patient Health Questionnaire depression scale (PHQ-8): severity
measure for depressive disorders [107].
The General Anxiety Disorder 7-item anxiety scale (GAD-7): severity
measure for anxiety [108];
The Capability Opportunity Motivation Behaviour Beliefs Questionnaire
(COM- BMQ), incorporating the validated self-report Beliefs about
Medicines Questionnaire - specific (Nebuliser adherence) (BMQ 21-
item) [109], customised by the team to identify perceived necessities
and concerns for nebuliser treatment. Elements of the COM-BMQ
map to logic model constructs #7, #29 and#33.
Project-specific items on belief, intention and confidence
Subjective adherence single question: self-report estimate of adherence
as a percentage. Maps to logic model construct #28.
Self-reported problems: identification of capability and opportunity
barriers to nebuliser adherence. Maps to logic model construct #33.
Concomitant medications: bespoke instrument, designed for this
research project.
Resource use form (inpatient IV days; routine clinic visits; unscheduled
outpatient contacts; unscheduled inpatient stays).
Prescription: a monthly prescription check to both check for data
transfer to CFHealthHub and review for an indication that the
prescription has changed
Objective Adherence to prescribed medication
Any treatment with IV antibiotics
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all the data in the study and had final responsibility for
the decision to submit for publication.
Results
Recruitment
We recruited between 23rd June and 30 September 2016.
Overall, 430 PWCF were reviewed for eligibility (Fig. 3). Of
these, 135 were eligible, 95 (70%) successfully contacted
and 64 (67%) of those contacted consented; 100% of the
intended sample size were therefore recruited, exceeding
the 75% target. A total of 33 participants were allocated to
the intervention group and 31 to the control group.
Participant characteristics
Participants entering the study had a median age of 27
and 56% were male (Table 2). Most participants were
from average (25%), low (23%) or least deprived (23%)
areas of deprivation. Mean baseline FEV1 percent pre-
dicted was 57.3. Full baseline characteristics tables can
be found in Additional file 4.
Fig. 3 Participant flow
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Retention
At study completion on 30th April 2017, 60 (94%: Interven-
tion = 32, Control =28) participants contributed exacerba-
tion data, therefore exceeding the target 85% retention rate
with respect to primary outcome data contribution. A total
of 57 (89%: Intervention = 30, Control = 27) contributed
FEV1 data; 59 (92%: Intervention = 31, Control = 28) con-
tributed follow-up questionnaire data and 48 (75%: Inter-
vention = 24, Control = 24) contributed 5 (±1) months of
adherence data (Fig. 4). Two participants died (not related
to RCT participation), one withdrew research consent, two
were lost to follow-up, and two withdrew from adherence
data collection (Intervention = 1, Control = 1).
Quality of primary clinical outcome data
There were 79 data collection sheets completed provid-
ing information on, the expected primary outcome for
the full trial, in those followed up for 5 (±1) months; 60
of the data collection sheets identified episodes that ful-
filled the primary outcome with at least 1 Fuchs’ symp-
tom and treatment with IV antibiotics. A total of 18
sheets were completed for episodes not treated with
IVABs, and one episode treated with IVAB did not meet
any of the modified Fuchs’ criteria. Of 60 that were in-
cluded in the analysis set, 35 exacerbations occurred in
intervention participants, 25 in control participants (see
Discussion). 33 participants experienced at least 1 ex-
acerbation (Intervention = 19 (60%), Control = 14 (50%)).
Adjusted IRR was 1.12 (95% CI: 0.66–1.94) indicating no
difference between treatment arms.
Other key clinical outcomes
Adjusting for baseline and site, there was a between-group
difference of 5% (95% CI -2 to 12%) in FEV1 percent pre-
dicted (Table 3). Figure 4 indicates a small difference
across treatments arms in numerator adjusted mean
weekly adherence during the study with the overall differ-
ence between treatment arms for the whole study period
being 10% (95% CI: -5.2 to 25.2), greater in the interven-
tion arm. Further details of secondary clinical outcomes
are available in Additional file 4. A total of eight adverse
events occurred; seven participants (11%) had at least one
adverse event, of which five were serious adverse events,
none related to the intervention. Of the five SAEs, 3/33
(9%) were in the intervention arm and 2/31 (7%) were in
the control arm. The 2 SAEs in the control arm were
deaths; there were no deaths in the intervention arm but 2
hospitalisations and 1 persistent or significant disability/
incapacity.
Acceptability and robustness of the trial procedures
The information sheet was described as ‘wordy’ and
questionnaires repetitive; otherwise, participants found
research procedures acceptable. Interventionists con-
firmed that they had no access to adherence data for
control patients, as required by trial procedures. MDT
members said a lack of resources and training precluded
contamination. There was no systematic strategy to in-
volve the wider CF team in the use of the adherence data
to support care and most data sharing was via the inter-
ventionist. This was partly a conscious strategy to avoid
contamination of the control subjects. Aside from the
new nebuliser and 2net Hub, control participants viewed
their care and approach to self-management as un-
affected, although one admitted making an effort to ad-
here because of the collection of adherence data.
Modifications to research procedures
Additional file 5 documents 10 technical changes made,
in relation to RCT procedures, to CFHH (n = 1), IT in-
frastructure (n = 1), and trial procedures (n = 8). To pre-
vent adherence data flatlines, nebulisers (#4) and 2net
Hubs (#5) are now paired at the factory. In the feasibility
study, a focus on RCT recruitment targets gave interven-
tionists inadequate time to deliver review visits (#18,
#24), critical for updating personalised action plans
(#25) and updating coping plans (#26). Therefore the
full-scale trial will also have a longer pro rata participant
accrual window. As there was inconsistency in comple-
tion of the case report form for exacerbations (primary
clinical outcome), changes have been made to training
and the case report forms for the main trial. Namely, the
modified form records if the clinical team considered
there to be a need for IVABs, whether these were
Table 2 Baseline characteristics by treatment arm
Intervention Control Overall
Age
n 33 31 64
Mean (SD) 31.6 (13.3) 27.8 (8.9) 29.7 (11.5)
Median (IQR) 28 (21,37) 26 (20,34) 27 (21,36)
Sex
Male 18 (55%) 18 (58%) 36 (56%)
Female 15 (45%) 13 (42%) 28 (44%)
Socioeconomic Status
Most deprived 6 (18%) 1 (3%) 7 (11%)
High deprivation 4 (12%) 7 (23%) 11 (17%)
Average 8 (24%) 8 (26%) 16 (25%)
Low deprivation 6 (18%) 9 (29%) 15 (23%)
Least deprived 9 (27%) 6 (19%) 15 (23%)
FEV1% Predicted
n 33 31 64
Mean (SD) 53.4 (19.4) 61.4 (22.7) 57.3 (21.3)
Median (IQR) 49.2 (39.4,61.9) 53.4 (43,80) 49.6 (41.9,76.7)
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accepted or not and subsequently whether any Fuchs’
criteria were met. Fuchs’ criteria are assessed regardless
of whether IVABs were accepted by the patient.
Discussion
The pilot RCT recruited well; in particular, recruitment
to the pilot was very high compared to other clinical CF
trials, illustrating the importance and relevance of adher-
ence to CF patients [81]. Participant retention and study
procedures were satisfactory, with no obvious contamin-
ation in the control arm.
In 24% of cases where clinicians competed the case re-
port form for an exacerbation, the criteria for this primary
clinical endpoint were not met (see Results | Quality of
primary clinical outcome data). This may have been, as in
other studies [82, 83], instances in which a clinician identi-
fied the clinical need for IVAB but patients chose treatment
with oral antibiotics. There is no universally-agreed def-
inition of an exacerbation [84, 85]. In our study, the
modified Fuchs’ criteria provided a relatively objective
assessment of clinical need; adding treatment with
IVABs ensured that only clinically severe episodes are
analysed. This definition goes some way to decreasing
ascertainment bias arising when closer monitoring
identifies less serious cases [84, 85], with less impact on
the health system than IVAB, and allows adjustment for
baseline adherence [86] via routinely collected data.
However, as adherence improves, patients may be more
willing to accept IVABs for exacerbations, which could
make ascertainment bias more marked. There was no
Table 3 Results of clinical outcomes
Intervention Control
n Median (IQR) n Median (IQR) IRR 95% CI
Number of exacerbations treated with IV antibiotics
with at least 1 Fuchs’ criteria in a 6 month period
(primary outcome definition)
Unadjusted 32 1 (0, 2) 28 0.5 (0, 2) 1.22 (0.69,2.21)
Adjusteda 1.12 (0.66,1.94)
n Mean (SD) n Mean (SD) Mean Diff 95% CI
FEV1 percent predicted Unadjusted 30 54.2 (21.1) 27 59 (23.9) −4.8 (−17,7.1)
Adjustedb 5 (−2,12)
aAdjusted for number of IV days in previous 12 months and site
bAdjusted for baseline and site
Fig. 4 Simple unadjusted and numerator-adjusted adherence
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difference in the rate of exacerbations/primary outcome
between treatment arms however the study was not
powered to detect an effect and was designed to assess
feasibility and the quality of the primary outcome data
as described above. Changes to CRF exacerbation forms
for the full-scale RCT will capture the number of cases
in which exacerbation criteria were met but IVABs were
refused by the patient, allowing detection of any ascer-
tainment bias. To better understand variation in adher-
ence over time, the full-scale trial will use differences in
mean group adherence over time, as expressed in Fig. 4,
in addition to pre/post measurements, which can miss
changes in adherence over the course of the trial (#35).
Future intervention research should consider the use of
continuous data to avoid missing patterns of adherence
behaviour between assessment timepoints.
Evidence that patient access to data improves health
outcomes or is cost-effective is generally poor and lacks
information about context and implementation [87, 88].
The full-scale RCT of our modified intervention at 19
UK centres (ISRCTN55504164) will provide high quality
evidence on the subject in 2020, with further process
evaluation and health-economic modelling. The problem
of how to embed routine use of adherence data by
healthcare professionals [89–93] is the subject of the
CFHealthHub Data Observatory (ISRCTN14464661).
This quality improvement project, onto which pilot sites
have now transitioned, will eventually host sites from
the full-scale RCT. The data it collects will be used to
develop theory and practical guidance about the collab-
orative use of adherence data that is generalisable to
multiple contexts [94, 95], with the aim of improving pa-
tient care and using NHS resources more efficiently [96].
The Observatory will act as a platform for efficient trials
[97, 98]. Shared processes and improvement activities
should increase the capacity and success of participating
cystic fibrosis clinical research teams [99].
Conclusions
We have developed a theory-based complex intervention
to help PWCF adhere to their medication. The pilot trial
observed a recruitment rate of eight participants per
centre per month, with acceptable levels of attrition. The
findings reported in this paper give high levels of confi-
dence that, with improved trial procedures, a full-scale
trial is feasible.
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